Fundação do ABC (Hospital Estadual Mário Covas)
Welcome,         Profile    Billing    Logout  
 5 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Site, Research
SAATELLITE-2, NCT05331885 / 2021-004979-14: A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2

Terminated
3
24
Europe, RoW
Suvratoxumab, AR-320, MEDI4893, Placebo
Aridis Pharmaceuticals, Inc.
Ventilator Associated Pneumonia, Staphylococcus Aureus
07/24
07/24
OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study)

Recruiting
3
123
Europe, Canada, US, RoW
PC945, Placebo
Pulmocide Ltd
Refractory IPA
03/26
04/26
KRYSTAL-10, NCT04793958 / 2020-004048-27: Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Active, not recruiting
3
461
Europe, Canada, US, RoW
MRTX849, Cetuximab, Erbitux, mFOLFOX6 Regimen, FOLFIRI Regimen
Mirati Therapeutics Inc., Mirati Therapeutics, Inc.
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
01/26
01/26
HARMONi-3, NCT05899608: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Recruiting
3
1080
Europe, Canada, US, RoW
Ivonescimab Injection, Pembrolizumab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
12/27
12/28
KRYSTAL-7, NCT04613596 / 2020-003101-58: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation

Hourglass Jul 2023 - Dec 2023 : Data from KRYSTAL-7 trial in combination with pembrolizumab for advanced NSCLC
Checkmark Updated data from KRYSTAL-7 trial for advanced NSCLC at ESMO-IO 2022
Dec 2022 - Dec 2022: Updated data from KRYSTAL-7 trial for advanced NSCLC at ESMO-IO 2022
Recruiting
2/3
806
Europe, Canada, Japan, US, RoW
Adagrasib, Pembrolizumab, Pemrolizumab
Mirati Therapeutics Inc.
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
10/28
10/29
RAINIER, NCT06496607: A Study to Evaluate Solriktug in Adult Participants With Asthma

Recruiting
2
124
US
NSI-8226, Placebo
Uniquity One (UNI), DevPro Biopharma
Asthma
12/25
04/26
ZION, NCT06496620: A Study to Evaluate Solrikitug in Participants With COPD

Recruiting
2
171
US
Biological: Solrikitug low dose, Biological: Solrikitug high dose, Placebo
Uniquity One (UNI), DevPro Biopharma
COPD
06/26
10/26
NCT06598462: A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults with Eosinophilic Esophagitis

Recruiting
2
157
US, RoW
Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo
Uniquity One (UNI)
Eosinophilic Esophagitis (EoE)
04/27
08/27
NCT05712889: Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Completed
1
29
US, RoW
VIP236 (Q3W), VIP236 (Q2W)
Vincerx Pharma, Inc.
Neoplasms
10/24
10/24
VNC-152-101, NCT02635672: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Completed
1
110
Europe, US, RoW
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, pembrolizumab, VIP152 (BAY 1251152) 15 mg
Vincerx Pharma, Inc.
Neoplasms
11/24
11/24
VNC-943-101, NCT06034275: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Jul 2022 - Dec 2023: Topline data from trial solid tumors
Recruiting
1
36
US
VIP943 (QW), VIP943 (BIW)
Vincerx Pharma, Inc.
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
05/25
12/25
VNC-152-102, NCT04978779: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Terminated
1
6
Europe, US
VIP152, BTKi
Vincerx Pharma, Inc.
Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
05/23
05/23
CA240-0007, NCT05245500: Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Recruiting
1
320
US
MRTX1719
Bristol-Myers Squibb
Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
04/26
04/26
Fernandes, Caio
SELSCH, NCT04589390: Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension

Recruiting
2
20
RoW
Selexipag
University of Sao Paulo General Hospital, Janssen-Cilag Ltd.
Pulmonary Hypertension, Schistosomiasis
11/21
03/22
OPENLINE, NCT06850792: imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce - A Randomized Multicenter Study

Not yet recruiting
N/A
72
RoW
Telemedicine-Based Adherence Support
University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension
04/28
04/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Site, Research
SAATELLITE-2, NCT05331885 / 2021-004979-14: A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2

Terminated
3
24
Europe, RoW
Suvratoxumab, AR-320, MEDI4893, Placebo
Aridis Pharmaceuticals, Inc.
Ventilator Associated Pneumonia, Staphylococcus Aureus
07/24
07/24
OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study)

Recruiting
3
123
Europe, Canada, US, RoW
PC945, Placebo
Pulmocide Ltd
Refractory IPA
03/26
04/26
KRYSTAL-10, NCT04793958 / 2020-004048-27: Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Active, not recruiting
3
461
Europe, Canada, US, RoW
MRTX849, Cetuximab, Erbitux, mFOLFOX6 Regimen, FOLFIRI Regimen
Mirati Therapeutics Inc., Mirati Therapeutics, Inc.
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
01/26
01/26
HARMONi-3, NCT05899608: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Recruiting
3
1080
Europe, Canada, US, RoW
Ivonescimab Injection, Pembrolizumab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
12/27
12/28
KRYSTAL-7, NCT04613596 / 2020-003101-58: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation

Hourglass Jul 2023 - Dec 2023 : Data from KRYSTAL-7 trial in combination with pembrolizumab for advanced NSCLC
Checkmark Updated data from KRYSTAL-7 trial for advanced NSCLC at ESMO-IO 2022
Dec 2022 - Dec 2022: Updated data from KRYSTAL-7 trial for advanced NSCLC at ESMO-IO 2022
Recruiting
2/3
806
Europe, Canada, Japan, US, RoW
Adagrasib, Pembrolizumab, Pemrolizumab
Mirati Therapeutics Inc.
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
10/28
10/29
RAINIER, NCT06496607: A Study to Evaluate Solriktug in Adult Participants With Asthma

Recruiting
2
124
US
NSI-8226, Placebo
Uniquity One (UNI), DevPro Biopharma
Asthma
12/25
04/26
ZION, NCT06496620: A Study to Evaluate Solrikitug in Participants With COPD

Recruiting
2
171
US
Biological: Solrikitug low dose, Biological: Solrikitug high dose, Placebo
Uniquity One (UNI), DevPro Biopharma
COPD
06/26
10/26
NCT06598462: A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults with Eosinophilic Esophagitis

Recruiting
2
157
US, RoW
Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo
Uniquity One (UNI)
Eosinophilic Esophagitis (EoE)
04/27
08/27
NCT05712889: Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Completed
1
29
US, RoW
VIP236 (Q3W), VIP236 (Q2W)
Vincerx Pharma, Inc.
Neoplasms
10/24
10/24
VNC-152-101, NCT02635672: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Completed
1
110
Europe, US, RoW
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, pembrolizumab, VIP152 (BAY 1251152) 15 mg
Vincerx Pharma, Inc.
Neoplasms
11/24
11/24
VNC-943-101, NCT06034275: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Jul 2022 - Dec 2023: Topline data from trial solid tumors
Recruiting
1
36
US
VIP943 (QW), VIP943 (BIW)
Vincerx Pharma, Inc.
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
05/25
12/25
VNC-152-102, NCT04978779: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Terminated
1
6
Europe, US
VIP152, BTKi
Vincerx Pharma, Inc.
Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
05/23
05/23
CA240-0007, NCT05245500: Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Recruiting
1
320
US
MRTX1719
Bristol-Myers Squibb
Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
04/26
04/26
Fernandes, Caio
SELSCH, NCT04589390: Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension

Recruiting
2
20
RoW
Selexipag
University of Sao Paulo General Hospital, Janssen-Cilag Ltd.
Pulmonary Hypertension, Schistosomiasis
11/21
03/22
OPENLINE, NCT06850792: imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce - A Randomized Multicenter Study

Not yet recruiting
N/A
72
RoW
Telemedicine-Based Adherence Support
University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension
04/28
04/28

Download Options